LUND, SWEDEN--(Marketwire - May 29, 2012) - Active Biotech invites analysts, investors and
media to Capital Markets Day on June 14, 2012.
When: Thursday, June 14, 2012 at 2-4 p.m. CET.
Where: Spårvagnshallarna, Birger Jarlsgatan 57 A, Stockholm, Sweden.
To attend:
Please send name & contact details to kapitalmarknadsdag@activebiotech.com or
call +46 (0)46 19 20 00, no later than June 10, 2012.
Active Biotech participants:
Tomas Leanderson, President & CEO
Göran Forsberg, Chief Business Officer
Program:
Overview of Active Biotech's project portfolio
The Capital Markets Day will also be available to follow via Active Biotech's
website www.activebiotech.com.
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with
unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy,
primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57-57 for Systemic Sclerosis and RhuDex®
for
RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the information contained in this
press
release in accordance with the Swedish Securities Market Act. This
information
was provided to the media for publication 1:00 p.m. CET on May 29, 2012.
Active Biotech invites to Capital Markets Day:
http://hugin.info/1002/R/1615546/515010.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1615546]
